Cantor Fitzgerald Issues Pessimistic Forecast for MiMedx Group (NASDAQ:MDXG) Stock Price

MiMedx Group (NASDAQ:MDXG) had its price objective reduced by stock analysts at Cantor Fitzgerald from $12.00 to $8.00 in a research note issued on Tuesday,Benzinga reports. The firm currently has an “overweight” rating on the stock. Cantor Fitzgerald’s target price points to a potential upside of 56.40% from the company’s previous close.

Several other research analysts also recently weighed in on the stock. Mizuho dropped their target price on shares of MiMedx Group from $12.00 to $10.00 and set an “outperform” rating on the stock in a research report on Wednesday, December 17th. Wall Street Zen raised shares of MiMedx Group from a “buy” rating to a “strong-buy” rating in a research note on Sunday, November 2nd. Lake Street Capital cut their target price on shares of MiMedx Group from $12.00 to $10.00 and set a “buy” rating on the stock in a research note on Tuesday, January 20th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of MiMedx Group in a research report on Monday, December 29th. Three analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $9.33.

MiMedx Group Price Performance

Shares of MDXG traded down $0.01 during trading hours on Tuesday, hitting $5.12. 57,858 shares of the company were exchanged, compared to its average volume of 991,009. The firm has a fifty day simple moving average of $6.05 and a 200-day simple moving average of $6.69. The company has a market capitalization of $757.53 million, a PE ratio of 19.06 and a beta of 1.59. The company has a debt-to-equity ratio of 0.07, a current ratio of 4.41 and a quick ratio of 3.95. MiMedx Group has a one year low of $4.89 and a one year high of $8.50.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. CWM LLC grew its holdings in MiMedx Group by 63.8% during the second quarter. CWM LLC now owns 4,857 shares of the company’s stock valued at $30,000 after purchasing an additional 1,892 shares during the last quarter. PNC Financial Services Group Inc. raised its holdings in MiMedx Group by 1,808.4% in the 2nd quarter. PNC Financial Services Group Inc. now owns 7,500 shares of the company’s stock worth $46,000 after acquiring an additional 7,107 shares during the period. Kemnay Advisory Services Inc. bought a new stake in MiMedx Group during the fourth quarter valued at about $48,000. State of Alaska Department of Revenue acquired a new position in shares of MiMedx Group during the 3rd quarter worth about $54,000. Finally, Headlands Technologies LLC bought a new stake in MiMedx Group during the 2nd quarter valued at approximately $72,000. Institutional investors and hedge funds own 79.15% of the company’s stock.

MiMedx Group Company Profile

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.